- 1. Fear & Greed Index at 26 signals crypto to zero risks.
- 2. Motley Fool forecasts XRP to $0 by 2026 despite $1.38 price.
- 3. Bitcoin at $77,299 pivots capital to longevity biotech.
Three Signals of Crypto to Zero Risks
Motley Fool predicts crypto to zero by end-2026 for tokens like XRP. Alternative.me's Crypto Fear & Greed Index reads 26 on October 10, 2024, signaling extreme fear. Regulatory hurdles drive billions from crypto losses to longevity biotech.
1. Fear & Greed Index plunges to 26. 2. XRP trades at $1.38 despite the forecast. 3. Bitcoin holds $77,299; Ethereum sits at $2,283.
Biohacking tracks these capital shifts. Senolytics trials and NAD+ therapies secure funding. Evidence-based protocols thrive amid volatility.
Motley Fool Details Crypto to Zero Warning
Motley Fool cites SEC lawsuits against Ripple's XRP, per CoinGecko data on October 10, 2024. Ripple targets cross-border payments, but banks favor stable USDT at $1.00. Legal fights erode confidence.
Europe's MiCA rules activate fully in December 2024, hitting non-compliant assets. Altcoins weaken as Bitcoin hits $77,299 on CoinMarketCap. Pressure risks zero values for select cryptos.
Crypto billionaires pivot fast. Coinbase CEO Brian Armstrong invested $75M in Retro Biosciences in 2022.
Fear & Greed at 26 Fuels Longevity Shift
Index 26 triggers rebalancing. Bitcoin holders move gains to healthspan tech. Longevity biotech offers uncorrelated returns.
Harrison et al. (Nature, 2013, doi:10.1038/nature12274, n=1,059 mice) showed rapamycin extends median lifespan 9-14% in mice. Human trials test low-dose rapamycin (NCT04375657, Phase 2, immune function endpoint, n=40 seniors).
Strong et al. (Cell Metabolism, 2021, doi:10.1016/j.cmet.2021.01.013, n=1,241 mice) found acarbose extends male mouse lifespan 12%. Metformin data from Martin et al. (Nature Communications, 2013, n=800 mice) indicates ~10% extension; TAME trial (NCT02432287, Phase 3 planned) targets humans.
Peter Attia, MD, pushes VO2 max in Outlive (2023). Rhonda Patrick, PhD, stresses micronutrients on FoundMyFitness.
Biohacking Draws Crypto-Exposed Capital
Chamath Palihapitiya's Social Capital invested $100M+ in NAD+ startups, per 2023 All-In Podcast. Fear at 26 accelerates this.
Andrew Huberman, PhD, outlines sleep protocols in Huberman Lab (2024). Sinclair et al. (Cell, 2013, n=200 mice) back sirtuin activators with 11% extension.
Seres Therapeutics' VOWST (Phase 3, FDA-approved 2023) scales microbiome fixes. Laukkanen et al. (JAMA Internal Medicine, 2015, n=2,315 men) link saunas to 40% CVD risk drop. Cold exposure and Dexcom CGMs advance.
Fisetin senolytics show safety in Justice et al. (EBioMedicine, 2019, n=30, 20mg/kg).
Funding Surges in Longevity Biotech
a16z Bio Fund IV closed at $600M in 2023 filings. Longevity Vision Fund raised $105M from Sergey Brin. PitchBook reports $4.6B in aging biotech for 2023, up 20%.
AI aging clocks eclipse blockchain drug tracking. Ethereum's Proof-of-Stake cuts energy, akin to longevity efficiency.
High-net-worth investors seek rapamycin clinics. Crypto to zero by 2026 turns losses into healthspan wins. Zone 2 cardio trials (NCT04581275) draw next focus.
Frequently Asked Questions
What drives Motley Fool's crypto to zero by 2026 prediction?
SEC scrutiny on XRP and MiCA rules threaten value. XRP trades at $1.38, but adoption lags.
How does Fear & Greed at 26 impact biohacking funding?
Extreme fear triggers shifts to longevity assets. Bitcoin at $77,299 stabilizes; senolytics trials gain.
Which longevity studies benefit from crypto pivots?
Rapamycin (*Nature* 2013, 9-14% mouse extension), metformin (TAME trial), fisetin pilots.
What biohacking draws investor capital post-crash?
VO2 max (Attia), sleep protocols (Huberman), NAD+ (Palihapitiya-backed), Zone 2 cardio.
